Dupixent – Dupixent is an investigational human monoclonal antibody in for the treatment of moderate-to-severe atopic dermatitis. In addition to AD, the compound is being evaluated in asthma, nasal polyposis and eosinophilic esophagitis.
Origin developed the brand name Dupixent for Sanofi Regeneron. Derived from ‘dupliumab’, ‘duo/durable/’ and ‘exact’, it is positive/active sounding with an innovative/futuristic tone. Dupixent suggests high-efficacy, targeted and superior patient benefits. It is impactful and memorable.